

Jan A Burger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5352342/jan-a-burger-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

19,043
citations

71
h-index

136
g-index

218
ext. papers

21,891
ext. citations

6.6
avg, IF

7.01
L-index

#	Paper	IF	Citations
210	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	2
209	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9	1.9	2
208	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.. <i>Blood Cancer Journal</i> , 2022 , 12, 43	7	1
207	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. <i>Leukemia</i> , 2021 ,	10.7	1
206	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021 , 35, 2621-2634	10.7	6
205	The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. <i>Blood Cancer Journal</i> , 2021 , 11, 57	7	5
204	Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021 , 102, 106520	2.7	6
203	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021 , 5, 1876-1883	7.8	14
202	CLL cells are moved by the MARCKS brothers. <i>Blood</i> , 2021 , 138, 503-504	2.2	0
201	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021 , 35, 3163-3175	10.7	5
200	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021 , 35, 3421-3429	10.7	5
199	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021 , 194, 61-68	4.5	1
198	Resistance Mutations to BTK Inhibitors Originate From the NF-B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. <i>Frontiers in Immunology</i> , 2021 , 12, 689472	8.4	6
197	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 1610-1620	10.7	4
196	Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 45-57	1.9	0
195	Integrating New Therapies for Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 275-285	2.2	1
194	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. <i>JAMA Oncology</i> , 2021 , 7, 1213-1219	13.4	17

193	Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. <i>Blood</i> , 2021 ,	2.2	6
192	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.. <i>British Journal of Haematology</i> , 2021 ,	4.5	5
191	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020 , 60, 130-137	1.9	1
190	Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2536-2537	1.9	6
189	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and ILLUMINATE). <i>Blood</i> , 2020 , 136, 25-26	2.2	1
188	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020 , 136, 42-43	2.2	7
187	Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. <i>Blood</i> , 2020 , 135, 510-513	2.2	6
186	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. <i>Leukemia</i> , 2020 , 34, 1588-1598	10.7	8
185	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology,the</i> , 2020 , 7, e724-e736	14.6	91
184	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020 , 97, 106432	2.7	16
183	Treatment of Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2020 , 383, 460-473	59.2	75
182	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2020 , 99, 2343-2349	3	2
181	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020 , 34, 787-798	10.7	185
180	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. <i>Clinical Cancer Research</i> , 2020 , 26, 3918-3927	12.9	69
179	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 134, 1811-1820	2.2	50
178	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology,the</i> , 2019 , 6, e100-e109	14.6	48
177	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019 , 380, 2095-2103	59.2	256
176	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019 , 133, 2031-2042	123	

175	Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. <i>British Journal of Haematology</i> , 2019 , 185, 852-864	4.5	14
174	Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. <i>Clinical Cancer Research</i> , 2019 , 25, 2372-2374	12.9	
173	Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. <i>British Journal of Haematology</i> , 2019 , 186, 175-180	4.5	5
172	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019 , 134, 851-859	2.2	151
171	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3461-3469	1.9	9
170	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. <i>British Journal of Haematology</i> , 2019 , 187, e1-e4	4.5	2
169	Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2019 , 187, 307-318	4.5	19
168	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363	7.1	152
167	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 2056-2068	2.2	10
166	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 184-188	4.5	5
165	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019 , 94, 554-562	7.1	20
164	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. <i>Blood</i> , 2019 , 134, 1951-1959	2.2	19
163	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019 , 3, 1799-1807	7.8	61
162	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. <i>Blood Advances</i> , 2019 , 3, 1533-1539	7.8	5
161	Bruton Tyrosine Kinase Inhibitors: Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 386-393	3.2	34
160	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019 , 33, 287-298	10.7	22
159	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , 2019 , 185, 606-608	4.5	5
158	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. <i>American Journal of Hematology</i> , 2019 , 94, E90-E93	7.1	12

157	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019 , 184, 558-569	4.5	51
156	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 1011-1019	2.2	120
155	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1000-1005	1.9	11
154	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2018 , 32, 2278-2281	10.7	3
153	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018 , 131, 1910-1919	2.2	267
152	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. <i>Nature Reviews Cancer</i> , 2018 , 18, 148-167	31.3	159
151	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018 , 131, 1820-1832	2.2	25
150	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>Onc Immunology</i> , 2018 , 7, e1417720	7.2	7
149	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018 , 215, 681-697	16.6	41
148	New pieces in the BTKi resistance puzzle. <i>Blood</i> , 2018 , 131, 1995-1996	2.2	
147	Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. <i>British Journal of Haematology</i> , 2018 , 180, 597-600	4.5	3
146	Survival adjusting for crossover: phase 3 study of ibrutinib . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2018 , 103, e249-e251	6.6	4
145	Duvelisib, an oral dual PI3K- γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. <i>American Journal of Hematology</i> , 2018 , 93, 1318-1326	7.1	33
144	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018 , 93, 1402-1410	7.1	19
143	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018 , 103, 1502-1510	6.6	82
142	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. <i>Cytokine</i> , 2018 , 109, 11-16	1.6	44
141	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018 , 3,	9.9	21
140	Duvelisib, a novel oral dual inhibitor of PI3K- δ/γ is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018 , 131, 877-887	2.2	150

139	Bruton® tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 31-42	5.9	45
138	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018 , 8, 369	5.3	15
137	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. <i>Leukemia</i> , 2018 , 32, 2388-2398	10.7	17
136	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 510-527	19.4	73
135	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 648-657.e15	2	45
134	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2017 , 198, 1740-1747	5.3	71
133	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 1149-1155	12.9	43
132	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017 , 123, 2268-2273	6.4	83
131	HSP90, a chaperone that can make you SYK. <i>Blood</i> , 2017 , 129, 542-544	2.2	1
130	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017 , 178, 286-291	4.5	47
129	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017 , 129, 2612-2615	2.2	89
128	Ibrutinib inhibits pre-BCR B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. <i>Blood</i> , 2017 , 129, 1155-1165	2.2	47
127	Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. <i>JCI Insight</i> , 2017 , 2, e89904	9.9	57
126	The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. <i>Frontiers in Immunology</i> , 2017 , 8, 1773	8.4	20
125	Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e494-e496	6.6	7
124	CLL progression after one cycle of FCR: Richter® transformation versus EBV-associated lympho-proliferation. <i>American Journal of Hematology</i> , 2017 , 92, 1113-1114	7.1	4
123	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e394-e396	6.6	8
122	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017 , 102, 1796-1805	6.6	150

121	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2154-2158	12.9	43
120	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2313-2324	12.9	35
119	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. <i>Nature Communications</i> , 2017 , 8, 2185	17.4	99
118	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. <i>Leukemia and Lymphoma</i> , 2016 , 57, 563-71	1.9	25
117	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016 , 1863, 401-413	4.9	125
116	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). <i>Current Topics in Microbiology and Immunology</i> , 2016 , 393, 123-142	3.3	38
115	Phase I study of single-agent CC-292, a highly selective Bruton [®] tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, e295-8	6.6	54
114	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2016 , 197, 2522-31	5.3	23
113	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016 , 7, 11589	17.4	220
112	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1077-89	4	11
111	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016 , 22, 2359-67	12.9	22
110	Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 233-233	2.2	54
109	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016 , 7, 65968-65981	3.3	67
108	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016 , 174, 425-36	4.5	21
107	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2016 , 101, e254-8	6.6	32
106	Obinutuzumab: the more the merrier?. <i>Blood</i> , 2016 , 127, 6-8	2.2	7
105	Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, E478-E479	7.1	16
104	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2015 , 27, 409-25	24.3	81

103	Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 385-91	2	22
102	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015 , 125, 3236-45	2.2	90
101	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015 , 125, 2497-506	2.2	529
100	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1643-50	1.9	93
99	The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2015 , 171, 281-284	4.5	4
98	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015 , 125, 2062-7	2.2	255
97	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 2915-22	2.2	92
96	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 2686-94	2.2	194
95	The microenvironment in chronic lymphocytic leukemia: biology and therapeutic translation 2015 , 56-71		
94	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer</i> , 2015 , 121, 3612-21	6.4	185
93	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 726-35	4.5	40
92	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 2425-37	59.2	950
91	The importance of the tissue microenvironment in hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 208-16	4.2	5
90	Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015 , 170, 125-8	4.5	10
89	Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. <i>Blood</i> , 2015 , 126, 1737-1737	2.2	7
88	Bruton tyrosine kinase (BTK) inhibitors in clinical trials. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 44-9	4.4	80
87	Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. <i>Clinical Cancer Research</i> , 2014 , 20, 548-56	12.9	66
86	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , 2014 , 15, 48-58	21.7	372

85	The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. <i>British Journal of Haematology</i> , 2014 , 166, 177-88	4.5	54
84	The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. <i>Blood</i> , 2014 , 123, 1032-9	2.2	145
83	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 1090-9	21.7	283
82	Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 13906-11	11.5	72
81	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. <i>Pharmacology & Therapeutics</i> , 2014 , 144, 338-48	13.9	43
80	CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2014 , 32, 897-904	2.2	118
79	Bruton [®] tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1830-9	2.2	80
78	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. <i>Blood</i> , 2014 , 123, 3727-32	2.2	109
77	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. <i>Blood</i> , 2014 , 123, 4132-5	2.2	70
76	Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. <i>Blood</i> , 2014 , 123, 3797-802	2.2	54
75	Ibrutinib: a paradigm shift in management of CLL. <i>Expert Review of Hematology</i> , 2014 , 7, 705-17	2.8	12
74	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. <i>Haematologica</i> , 2014 , 99, 1350-5	6.6	55
73	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. <i>Seminars in Cancer Biology</i> , 2014 , 24, 71-81	12.7	203
72	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014 , 124, 1990-1990	2.2	9
71	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients \geq 65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2014 , 124, 1994-1994	2.2	16
70	Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma. <i>Blood</i> , 2014 , 124, 326-326	2.2	6
69	B cell receptor signaling in chronic lymphocytic leukemia. <i>Trends in Immunology</i> , 2013 , 34, 592-601	14.4	207
68	Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 584-91	2.2	127

67	The CLL cell microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 792, 25-45	3.6	14
66	Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. <i>Blood</i> , 2013 , 121, 1501-9	2.2	93
65	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). <i>Leukemia and Lymphoma</i> , 2013 , 54, 2385-91	1.9	107
64	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2013 , 369, 32-42	59.2	1656
63	The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. <i>PLoS ONE</i> , 2013 , 8, e83830	3.7	67
62	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 1630-1630	2.2	25
61	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013 , 122, 525-525	2.2	25
60	Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 26-33	4.4	41
59	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. <i>Blood</i> , 2012 , 119, 1182-9	2.2	491
58	Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. <i>Leukemia and Lymphoma</i> , 2012 , 53, 3-4	1.9	2
57	Development of novel CXCR4-based therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 341-53	5.3	67
56	Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. <i>Nature Cell Biology</i> , 2012 , 14, 276-86	23.4	234
55	The times they are a-changin prognostic markers in the new era of BCR-targeting therapies for CLL. <i>Expert Opinion on Medical Diagnostics</i> , 2012 , 6, 49-57		3
54	Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience 2012 , 369-385		
53	Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. <i>Current Opinion in Oncology</i> , 2012 , 24, 643-9	4.2	49
52	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. <i>Haematologica</i> , 2012 , 97, 599-607	6.6	54
51	The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2012 , 120, 187-187	2.2	18
50	The Bruton Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase II/III Study. <i>Blood</i> , 2012 , 120, 189-189	2.2	16

49	Cell Trafficking in Chronic Lymphocytic Leukemia. <i>Open Journal of Hematology</i> , 2012 , 3,		51
48	The Bone Marrow Microenvironment and Its Impact in Acute and Chronic B Cell Malignancies 2012 , 35-45		
47	Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. <i>Human Pathology</i> , 2011 , 42, 1989-2000	3.7	16
46	Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. <i>Blood</i> , 2011 , 117, 3016-24	2.2	152
45	CCL3 (MIP-1 β) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 1662-9	2.2	98
44	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 3489-98	2.2	145
43	The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. <i>Seminars in Cancer Biology</i> , 2011 , 21, 308-12	12.7	46
42	Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. <i>Cancer</i> , 2011 , 117, 4689-95	6.4	34
41	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 2, 94-8	1.9	14
40	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4088-95	2.2	105
39	Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. <i>Cancer Research</i> , 2011 , 71, 3831-40	10.1	70
38	Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011 , 2011, 96-103	3.1	134
37	Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 621-30	3.5	63
36	Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. <i>Blood</i> , 2011 , 118, 3818-23	2.2	83
35	The phosphoinositide 3Kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 3603-12	2.2	421
34	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. <i>Blood</i> , 2011 , 118, 1760-1760	2.2	4
33	The great imitator: systemic nocardiosis mimicking Richter \circledast transformation in relapsed chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, e732-4	2.2	10
32	BCR-mediated decrease of CXCR4 and CD62L in CLL. <i>Cancer Research</i> , 2010 , 70, 5194; author reply 5195	10.1	7

31	Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. <i>Blood</i> , 2010 , 116, 1083-91	2.2	48
30	Angiopoietin-2 in CLL. <i>Blood</i> , 2010 , 116, 508-9	2.2	13
29	Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. <i>Seminars in Cancer Biology</i> , 2010 , 20, 424-30	12.7	88
28	Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 2450-2450	2.2	18
27	Bruton® Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.. <i>Blood</i> , 2010 , 116, 45-45	2.2	2
26	The Bruton® Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. <i>Blood</i> , 2010 , 116, 57-57	2.2	15
25	CXCR4 chemokine receptor antagonists: perspectives in SCLC. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 481-90	5.9	54
24	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. <i>Blood</i> , 2009 , 114, 4441-50	2.2	260
23	The microenvironment in mature B-cell malignancies: a target for new treatment strategies. <i>Blood</i> , 2009 , 114, 3367-75	2.2	443
22	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. <i>Blood</i> , 2009 , 113, 149-53	2.2	131
21	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. <i>Blood</i> , 2009 , 113, 4604-13	2.2	141
20	Isoform-selective phosphoinositide 3Kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. <i>Blood</i> , 2009 , 113, 5549-57	2.2	125
19	High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. <i>Blood</i> , 2009 , 113, 3050-8	2.2	238
18	The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. <i>Blood</i> , 2009 , 114, 2560-1; author reply 2561-2	2.2	20
17	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. <i>Blood</i> , 2009 , 114, 1029-37	2.2	196
16	The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. <i>British Journal of Haematology</i> , 2007 , 137, 288-96	4.5	127
15	CXCR4 is a prognostic marker in acute myelogenous leukemia. <i>Blood</i> , 2007 , 109, 786-91	2.2	252
14	Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 110, 3316-25	2.2	170

13	Fledgling prognostic markers in CLL. <i>Blood</i> , 2007 , 110, 3820-3821	2.2	1
12	Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2427-30	1.9	3
11	CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. <i>Blood</i> , 2006 , 107, 1761-7	2.2	956
10	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 106, 1824-30	2.2	245
9	CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. <i>Oncogene</i> , 2005 , 24, 4462-71	9.2	218
8	The CXCR4 Score: A New Prognostic Marker in Acute Myelogenous Leukemia.. <i>Blood</i> , 2004 , 104, 1072-1072	2.2	3
7	CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). <i>British Journal of Haematology</i> , 2003 , 122, 579-89	4.5	63
6	Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. <i>Oncogene</i> , 2003 , 22, 8093-101	9.2	227
5	Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 461-6	1.9	119
4	Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 1030-7	2.2	196
3	Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2001 , 107, 305-15	15.9	136
2	Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. <i>Blood</i> , 2000 , 96, 2655-2663	2.2	582
1	Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells. <i>Blood</i> , 1999 , 94, 3658-3667	2.2	391